FDA Approves Less Frequent Lebrikizumab Dosing

• by Kathryn Wighton

• June 10, 2026

Daily Itch Duration Linked to Quality-of-Life Burden

Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.

• by Andrea Surnit

• July 30, 2026

• 3 min

Connected Health May Match In-Person AD Care

A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.

• by Andrea Surnit

• July 9, 2026

• 3 min

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

• by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

• June 19, 2026